Feature | September 14, 2012

SCAI Launches Cath Lab AUC and Guidelines App

AUC calculator app is latest addition to SCAI Quality Improvement Toolkit

September 14, 2012 — Coronary revascularization appropriate use criteria (AUC) are now just a click away with the new SCAI Quality Improvement Toolkit (SCAI-QIT) AUC and Guidelines App, launched this week by the Society for Cardiovascular Angiography and Interventions (SCAI).


“The new app is a calculator tool that makes it simple to access the AUC on heart revascularization without having to carry around printed documents,” said Kalon Ho, M.D., FSCAI, architect of the new tool. “While we don’t intend for this tool to replace clinical judgment, we do hope it provides easier access to information that can guide the cath lab team’s decisions.”


Once members of the cardiac catheterization lab team input facts about a patient’s case, the app will indicate where a “typical” case with those same characteristics would fall on a spectrum of “appropriate,” “uncertain” or “inappropriate” for revascularization, as defined by the latest recommendations from leading cardiology societies, including SCAI and the American College of Cardiology Foundation, among others. Interventional cardiologists can then use that information to make recommendations for treatment of individual patients’ symptoms and conditions. 


SCAI’s calculator app also recognizes that complete documentation is essential in today’s healthcare environment. The app providers users with key data, including the relevant AUC scenario number, the indication score, a summary of the patient’s case and a link to a printer-friendly reporting sheet that can be added to the patient’s chart.  


In coming months, SCAI will expand the app with new modules to help healthcare providers access interventional cardiology guidelines and additional AUC, including those for diagnostic cardiac catheterization. Plans are also underway for the app to include options for interfacing with electronic health records (EHR), further assisting providers with documentation.


The AUC and Guidelines App is part of the expanded SCAI-QIT developed by SCAI’s Quality Improvement Committee to provide tools and resources that help both facilities and providers deliver consistent quality care to cath lab patients. Currently tools focus on guidelines and AUC, national database participation, inventory management, pre-procedure activities, operator and staff requirements, procedural quality and best practices, as well as facility and environmental issues. Each tool is regularly updated to incorporate the latest guidelines, regulatory requirements and feedback from the many SCAI Quality Champions who are using the tools in cath labs around the world.


“The SCAI-QIT has become an important resource for continuously improving cath lab quality. Within months of its launch, interventional cardiologists began telling us how SCAI-QIT helps them identify and address opportunities for improvement,” said SCAI Immediate Past President Christopher J. White, M.D., FSCAI. “The new AUC Calculator App is an example of a tool that will help cath lab teams easily access information supportive of high-quality, evidence-based patient care.”


The SCAI-QIT was developed with founding support from Daiichi Sankyo Lilly and support from AstraZeneca.


For more information: www.SCAI-QIT.org


Related Content

Sunshine Heart, C-Pulse, circulatory support system, update
News | Heart Failure| August 03, 2015
Sunshine Heart announced plans to commence a first-in-human study using its novel C-Pulse transcutaneous energy...
Pie Medical Imaging, CAAS IntraVascular 2.0, OCT, IVUS, NIRS-IVUS
Technology | Intravascular Imaging| August 03, 2015
Pie Medical Imaging announced the release of CAAS IntraVascular 2.0, the dedicated software for analysis of...
Products | Intravascular Imaging| August 03, 2015
European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic

Boston Scientific's Eluvia drug-eluting vascular stent system. Image courtesy of Boston Scientific.

Feature | Stents| July 31, 2015
According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents...
Hansen Medical, Magellan 10 French Robotic Catheter, FDA 510(k) clearance
Technology | Robotic Systems| July 29, 2015
The Magellan 10 French Robotic Catheter from Hansen Medical is indicated for use in the peripheral vasculature.
Products | Guidewires| July 28, 2015
The Safari2 Pre-Shaped Guidewire.
CSI, ViperWire Advance Peripheral Guide Wire with Flex Tip, Stealth, Diamondback

Diamondback 360 Peripheral OAS image courtesy of Cardiovascular Systems Inc.

Technology | Atherectomy Devices| July 22, 2015
Cardiovascular Systems Inc. announced that it has received U.S. Food and Drug Administration (FDA) clearance for its...
The Medicines Company, bivalirudin, Angiomax, litigation, Hospira Inc.
News | Cath Lab| July 22, 2015
The Medicines Company announced the U.S. Court of Appeals for the Federal Circuit Court has ruled against the company...
Boston Scientific, fully absorbable scaffold, FAST study, resorbable
Feature | Stents Bioresorbable| July 20, 2015
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully...
Veryan Medical, BioMimics 3D femoropopliteal stent, MIMICS-2 study, PAD
News | Stents Peripheral| July 17, 2015
Veryan Medical announced that the first subject has been enrolled in their MIMICS-2 study at Universitäts-Herzzentrum...
Overlay Init